ArticleTissue engineering. Part C, Methods2023
The Upscale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies.
Article in Tissue engineering. Part C, Methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Article
- Avenanthramide C and chondroitin sulphate promote chondrogenic differentiation of adipose-derived mesenchymal stem cells.Scientific reports · 2026Article
- Article
- A Comprehensive Review of Auto- and Allogeneic Chondrocyte Transplantation in Animals and Humans From 1965 to 2025.Cartilage · 2025Article
- Developing Up-Scale Allogeneic Chondrocyte Therapies Using Juvenile Donor Cartilage.International journal of molecular sciences · 2025Article
- Latest Advances in Chondrocyte-Based Cartilage Repair.Biomedicines · 2024Review
- Treatment of knee cartilage lesions in 2024: From hyaluronic acid to regenerative medicine.Journal of experimental orthopaedics · 2024Review
- Autologous and Allogeneic Cytotherapies for Large Knee (Osteo)Chondral Defects: Manufacturing Process Benchmarking and Parallel Functional Qualification.Pharmaceutics · 2023Article
- Cartilage Defect Treatment Using High-Density Autologous Chondrocyte Implantation (HD-ACI).Bioengineering (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Allogeneic chondrocyte therapies need to be developed to allow more individuals to be treated with a cell therapy for cartilage repair and to reduce the burden and cost of the current two-stage autologous procedures. Upscale manufacture of chondrocytes using a bioreactor could help provide an off-the-shelf allogeneic chondrocyte therapy with many doses being produced in a single manufacturing run. In this study, we assess a good manufacturing practice-compliant hollow-fiber bioreactor (Quantum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.